A clinical-biological risk stratification model for resected gastric cancer: Prognostic impact of HER2, FHIT, AND APC expression status

E. Bria, G. De Manzoni, S. Beghelli, A. Tomezzoli, S. Barbi, C. Di Gregorio, M. Scardoni, E. Amato, M. Frizziero, I. Sperduti, V. Corbo, M. Brunelli, S. Bersani, G. Tortora, A. Scarpa

Research output: Contribution to journalArticle

Abstract

Background: To obtain a prognostic stratification model for resected gastric cancer patients. Patients and methods: Clinicopathological and molecular data (expression of Cdx2, Apc, β-catenin, E-cadherin, Fhit, p53, and human epidermal growth factor receptor-2 (Her2); HER2 and TOPO2A gene copy number; PIK3CA mutations; microsatellite instability) were correlated to cancer-specific/overall survival (CSS/OS) using a Cox model. Individual patient probability (IPP) was estimated by logistic equation. A continuous score to identify risk-classes was derived according to the model ratios. Results: Two-hundred eight patients were studied (median follow-up 20 months). At multivariate analysis, sex, stage, margins, location, nodes, Apc, and Fhit were independent predictors for CSS; the same factors (and age and Her2, except Fhit) predicted OS. Multivariate model predicted IPP with high prognostic accuracy (0.90 for CSS; 0.91 for OS). A two-class model significantly separated lowand high-risk patients for CSS (23.4% and 85.6%, P <0.0001) and OS (21.4% and 82.0%, P <0.0001). A three-class model differentiated low-, intermediate-, and high-risk patients for CSS (6.3%, 35.3%, and 88.0%, P <0.0001) and OS (6.1%, 34.6%, and 86.5%, P <0.0001). Conclusions: A risk classification system comprising the immunohistochemical expression of three proteins (Apc, Fhit, and Her2) and five clinicopathological parameters (stage, resected nodes, margins, location, and sex) accurately separates the resected gastric cancer patients into three classes of risk.

Original languageEnglish
Article numbermds506
Pages (from-to)693-701
Number of pages9
JournalAnnals of Oncology
Volume24
Issue number3
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Stomach Neoplasms
erbB-2 Genes
Catenins
Microsatellite Instability
Gene Dosage
Age Factors
Cadherins
Proportional Hazards Models
Multivariate Analysis
Mutation
Survival
human ERBB2 protein
Neoplasms
Proteins

Keywords

  • Apc
  • Fhit
  • Gastric cancer
  • Her2
  • Prognosis
  • Score

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Bria, E., De Manzoni, G., Beghelli, S., Tomezzoli, A., Barbi, S., Di Gregorio, C., ... Scarpa, A. (2013). A clinical-biological risk stratification model for resected gastric cancer: Prognostic impact of HER2, FHIT, AND APC expression status. Annals of Oncology, 24(3), 693-701. [mds506]. https://doi.org/10.1093/annonc/mds506

A clinical-biological risk stratification model for resected gastric cancer : Prognostic impact of HER2, FHIT, AND APC expression status. / Bria, E.; De Manzoni, G.; Beghelli, S.; Tomezzoli, A.; Barbi, S.; Di Gregorio, C.; Scardoni, M.; Amato, E.; Frizziero, M.; Sperduti, I.; Corbo, V.; Brunelli, M.; Bersani, S.; Tortora, G.; Scarpa, A.

In: Annals of Oncology, Vol. 24, No. 3, mds506, 03.2013, p. 693-701.

Research output: Contribution to journalArticle

Bria, E, De Manzoni, G, Beghelli, S, Tomezzoli, A, Barbi, S, Di Gregorio, C, Scardoni, M, Amato, E, Frizziero, M, Sperduti, I, Corbo, V, Brunelli, M, Bersani, S, Tortora, G & Scarpa, A 2013, 'A clinical-biological risk stratification model for resected gastric cancer: Prognostic impact of HER2, FHIT, AND APC expression status', Annals of Oncology, vol. 24, no. 3, mds506, pp. 693-701. https://doi.org/10.1093/annonc/mds506
Bria, E. ; De Manzoni, G. ; Beghelli, S. ; Tomezzoli, A. ; Barbi, S. ; Di Gregorio, C. ; Scardoni, M. ; Amato, E. ; Frizziero, M. ; Sperduti, I. ; Corbo, V. ; Brunelli, M. ; Bersani, S. ; Tortora, G. ; Scarpa, A. / A clinical-biological risk stratification model for resected gastric cancer : Prognostic impact of HER2, FHIT, AND APC expression status. In: Annals of Oncology. 2013 ; Vol. 24, No. 3. pp. 693-701.
@article{356380a9bbb24659898cc8214fb85a78,
title = "A clinical-biological risk stratification model for resected gastric cancer: Prognostic impact of HER2, FHIT, AND APC expression status",
abstract = "Background: To obtain a prognostic stratification model for resected gastric cancer patients. Patients and methods: Clinicopathological and molecular data (expression of Cdx2, Apc, β-catenin, E-cadherin, Fhit, p53, and human epidermal growth factor receptor-2 (Her2); HER2 and TOPO2A gene copy number; PIK3CA mutations; microsatellite instability) were correlated to cancer-specific/overall survival (CSS/OS) using a Cox model. Individual patient probability (IPP) was estimated by logistic equation. A continuous score to identify risk-classes was derived according to the model ratios. Results: Two-hundred eight patients were studied (median follow-up 20 months). At multivariate analysis, sex, stage, margins, location, nodes, Apc, and Fhit were independent predictors for CSS; the same factors (and age and Her2, except Fhit) predicted OS. Multivariate model predicted IPP with high prognostic accuracy (0.90 for CSS; 0.91 for OS). A two-class model significantly separated lowand high-risk patients for CSS (23.4{\%} and 85.6{\%}, P <0.0001) and OS (21.4{\%} and 82.0{\%}, P <0.0001). A three-class model differentiated low-, intermediate-, and high-risk patients for CSS (6.3{\%}, 35.3{\%}, and 88.0{\%}, P <0.0001) and OS (6.1{\%}, 34.6{\%}, and 86.5{\%}, P <0.0001). Conclusions: A risk classification system comprising the immunohistochemical expression of three proteins (Apc, Fhit, and Her2) and five clinicopathological parameters (stage, resected nodes, margins, location, and sex) accurately separates the resected gastric cancer patients into three classes of risk.",
keywords = "Apc, Fhit, Gastric cancer, Her2, Prognosis, Score",
author = "E. Bria and {De Manzoni}, G. and S. Beghelli and A. Tomezzoli and S. Barbi and {Di Gregorio}, C. and M. Scardoni and E. Amato and M. Frizziero and I. Sperduti and V. Corbo and M. Brunelli and S. Bersani and G. Tortora and A. Scarpa",
year = "2013",
month = "3",
doi = "10.1093/annonc/mds506",
language = "English",
volume = "24",
pages = "693--701",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "3",

}

TY - JOUR

T1 - A clinical-biological risk stratification model for resected gastric cancer

T2 - Prognostic impact of HER2, FHIT, AND APC expression status

AU - Bria, E.

AU - De Manzoni, G.

AU - Beghelli, S.

AU - Tomezzoli, A.

AU - Barbi, S.

AU - Di Gregorio, C.

AU - Scardoni, M.

AU - Amato, E.

AU - Frizziero, M.

AU - Sperduti, I.

AU - Corbo, V.

AU - Brunelli, M.

AU - Bersani, S.

AU - Tortora, G.

AU - Scarpa, A.

PY - 2013/3

Y1 - 2013/3

N2 - Background: To obtain a prognostic stratification model for resected gastric cancer patients. Patients and methods: Clinicopathological and molecular data (expression of Cdx2, Apc, β-catenin, E-cadherin, Fhit, p53, and human epidermal growth factor receptor-2 (Her2); HER2 and TOPO2A gene copy number; PIK3CA mutations; microsatellite instability) were correlated to cancer-specific/overall survival (CSS/OS) using a Cox model. Individual patient probability (IPP) was estimated by logistic equation. A continuous score to identify risk-classes was derived according to the model ratios. Results: Two-hundred eight patients were studied (median follow-up 20 months). At multivariate analysis, sex, stage, margins, location, nodes, Apc, and Fhit were independent predictors for CSS; the same factors (and age and Her2, except Fhit) predicted OS. Multivariate model predicted IPP with high prognostic accuracy (0.90 for CSS; 0.91 for OS). A two-class model significantly separated lowand high-risk patients for CSS (23.4% and 85.6%, P <0.0001) and OS (21.4% and 82.0%, P <0.0001). A three-class model differentiated low-, intermediate-, and high-risk patients for CSS (6.3%, 35.3%, and 88.0%, P <0.0001) and OS (6.1%, 34.6%, and 86.5%, P <0.0001). Conclusions: A risk classification system comprising the immunohistochemical expression of three proteins (Apc, Fhit, and Her2) and five clinicopathological parameters (stage, resected nodes, margins, location, and sex) accurately separates the resected gastric cancer patients into three classes of risk.

AB - Background: To obtain a prognostic stratification model for resected gastric cancer patients. Patients and methods: Clinicopathological and molecular data (expression of Cdx2, Apc, β-catenin, E-cadherin, Fhit, p53, and human epidermal growth factor receptor-2 (Her2); HER2 and TOPO2A gene copy number; PIK3CA mutations; microsatellite instability) were correlated to cancer-specific/overall survival (CSS/OS) using a Cox model. Individual patient probability (IPP) was estimated by logistic equation. A continuous score to identify risk-classes was derived according to the model ratios. Results: Two-hundred eight patients were studied (median follow-up 20 months). At multivariate analysis, sex, stage, margins, location, nodes, Apc, and Fhit were independent predictors for CSS; the same factors (and age and Her2, except Fhit) predicted OS. Multivariate model predicted IPP with high prognostic accuracy (0.90 for CSS; 0.91 for OS). A two-class model significantly separated lowand high-risk patients for CSS (23.4% and 85.6%, P <0.0001) and OS (21.4% and 82.0%, P <0.0001). A three-class model differentiated low-, intermediate-, and high-risk patients for CSS (6.3%, 35.3%, and 88.0%, P <0.0001) and OS (6.1%, 34.6%, and 86.5%, P <0.0001). Conclusions: A risk classification system comprising the immunohistochemical expression of three proteins (Apc, Fhit, and Her2) and five clinicopathological parameters (stage, resected nodes, margins, location, and sex) accurately separates the resected gastric cancer patients into three classes of risk.

KW - Apc

KW - Fhit

KW - Gastric cancer

KW - Her2

KW - Prognosis

KW - Score

UR - http://www.scopus.com/inward/record.url?scp=84874560562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874560562&partnerID=8YFLogxK

U2 - 10.1093/annonc/mds506

DO - 10.1093/annonc/mds506

M3 - Article

C2 - 23131390

AN - SCOPUS:84874560562

VL - 24

SP - 693

EP - 701

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 3

M1 - mds506

ER -